D-Luciferin: High-Affinity Firefly Luciferase Substrate for Bioluminescence Imaging

Executive Summary: D-Luciferin (CAS 2591-17-5) is a gold-standard, membrane-permeable substrate for firefly luciferase-based bioluminescent assays (APExBIO). It exhibits a low Michaelis constant (Km ~2 μM), conferring high affinity and enabling ultrasensitive detection of intracellular ATP both in vitro and in vivo [He et al., 2025]. D-Luciferin’s robust performance facilitates non-invasive imaging of tumor burden, pharmacodynamics, and gene expression dynamics [internal]. APExBIO supplies D-Luciferin (B6040) with >98% purity, validated by HPLC, NMR, and MSDS documentation. Its use underpins reproducibility and translational impact in modern preclinical studies.

Biological Rationale

D-Luciferin is the natural substrate for firefly luciferase (Photinus pyralis). Upon enzyme-mediated oxidation, D-Luciferin emits light in the presence of ATP, oxygen, and Mg²⁺ ions. The intensity of bioluminescence is directly proportional to ATP concentration, making this system a sensitive reporter of cellular viability, gene expression, and metabolic status (APExBIO). This property is foundational to bioluminescence imaging (BLI), enabling real-time, non-invasive monitoring of biological processes in living organisms [contrast: this article extends by detailing substrate parameters]. D-Luciferin’s membrane permeability allows for efficient delivery to intracellular luciferase, supporting both in vitro and in vivo applications without the need for cell lysis or permeabilization.

Mechanism of Action of D-Luciferin

Firefly luciferase catalyzes the oxidation and decarboxylation of D-Luciferin in the presence of ATP and O₂ (He et al., 2025). The reaction proceeds as follows:

• D-Luciferin + ATP + O₂ --(luciferase)--> Oxyluciferin + AMP + CO₂ + Light (λmax ≈ 560 nm)

The Michaelis constant (Km) for D-Luciferin is approximately 2 μM, indicating high substrate-enzyme affinity ([internal: this article adds purity/storage details]). D-Luciferin is membrane-permeable, enabling rapid intracellular access. Photon emission is detected quantitatively, providing a linear readout of ATP levels or gene expression when luciferase is expressed under promoter control. This reaction is stoichiometric and does not require additional cofactors beyond ATP, oxygen, and Mg²⁺.

Evidence & Benchmarks

• D-Luciferin demonstrates a Km of ~2 μM for firefly luciferase, supporting high sensitivity and low background (He et al., 2025).
• APExBIO’s D-Luciferin (B6040) enables quantitative in vivo imaging of tumor burden, gene expression, and pharmacodynamic responses (APExBIO).
• In immunotherapy research, D-Luciferin-based BLI was used to monitor genetic engineering efficacy and T cell infiltration in solid tumor models (He et al., 2025, see Methods).
• Validated for both in vitro and in vivo bioluminescent ATP detection assays, with reliable performance at concentrations ≥28 mg/mL in DMSO (internal).
• Supplied at >98% purity, batch-tested by HPLC, NMR, and MSDS, ensuring reproducibility across experiments (APExBIO).

Applications, Limits & Misconceptions

D-Luciferin is central to bioluminescent ATP detection, non-invasive tumor burden assessment, and promoter-driven luciferase gene expression monitoring. It is widely used for:

• Sensitive, real-time quantification of intracellular ATP in living cells and animal models (internal).
• Tracking tumor growth, metastasis, and pharmacodynamic responses in oncology research (internal: this article is updated here with new immunotherapy data).
• Evaluating promoter activity and gene expression dynamics in genetic engineering studies (He et al., 2025).

Common Pitfalls or Misconceptions

• D-Luciferin is not compatible with non-firefly luciferase systems (e.g., Renilla luciferase, NanoLuc); it is specific for Photinus pyralis luciferase (APExBIO).
• It is insoluble in water and ethanol; proper dissolution requires DMSO at ≥28 mg/mL.
• Long-term storage of D-Luciferin solutions is not recommended due to instability; always prepare fresh aliquots (APExBIO).
• Bioluminescent signal is ATP-dependent; cell death or metabolic inhibitors may cause false-negative results unrelated to reporter gene activity.
• Signal strength is affected by tissue depth and optical scattering in in vivo imaging; quantification should be calibrated accordingly.

Workflow Integration & Parameters

APExBIO’s D-Luciferin (B6040) integrates seamlessly into standard luciferase reporter assays and bioluminescence imaging workflows. For in vitro use, dissolve D-Luciferin in DMSO to ≥28 mg/mL and dilute in compatible buffers immediately prior to use. For in vivo BLI, administer D-Luciferin intraperitoneally in rodents at 150 mg/kg body weight, image within 10–15 min post-injection (He et al., 2025). Store powder at -20°C; avoid repeated freeze-thaw of solutions. Shipping is performed on blue ice to maintain stability. The product is supplied with HPLC, NMR, and MSDS documentation, supporting regulatory and reproducibility requirements. For troubleshooting and advanced protocols, see D-Luciferin: Gold-Standard Firefly Luciferase Substrate for Imaging (this article adds product-specific QC and handling guidelines).

Conclusion & Outlook

D-Luciferin remains the benchmark substrate for firefly luciferase-based assays, facilitating high-sensitivity, non-invasive monitoring of ATP, gene expression, and tumor burden in preclinical research. APExBIO’s B6040 formulation delivers validated purity and robust performance, supporting reproducibility in translational studies. Advances in genetic engineering and immunotherapy research increasingly rely on D-Luciferin-based BLI for functional validation and pharmacodynamics. Future developments may optimize signal detection and multiplexing, but D-Luciferin’s core utility remains unmatched for photonic readouts in living systems.